[1] Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology,2020,72(2):671-722.
[2] Wang G, Tanaka A, Zhao H, et al.The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int,2021,15(2):223-257.
[3] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis.J Hepatol,2015,63(4):971-1004.
[4] Sebode M, Hartl J, Vergani D, et al.Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. Liver Int,2018,38(1):15-22.
[5] Robinson DP, Klein SL.Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis.Horm Behav,2012,62(3):263-271.
[6] Buchel E, Van Steenbergen W, Nevens F, et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol,2002,97(12):3160-3165.
[7] Sharma R, Simon TG, Stephansson O, et al. Pregnancy Outcomes in Women With Autoimmune Hepatitis-A Nationwide Population-based Cohort Study With Histopathology. Clin Gastroenterol Hepatol,2021,S1542-3565(21)01348-3.
[8] Stokkeland K, Ludvigsson JF, Hultcrantz R, et al.Increased risk of preterm birth in women with autoimmune hepatitis-a nationwide cohort study. Liver Int,2016,36(1):76-83.
[9] Sarkar M, Brady CW, Fleckenstein J, et al.Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Live Diseases. Hepatology, 2021, 73(1):318-365.
[10] Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep,2016,65(3):1-103.
[11] Inderal (propranolol hydrochloride) tablets. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020246s036lbl.pdf.
[12] Westbrook RH, Yeoman AD,O'Grady JG, et al.Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy. Clin Gastroenterol Hepatol,2011,9(8):694-699.
[13] Gonsalkorala ES, Cannon MD, Lim TY, et al. Non-Invasive Markers (ALBI and APRI) Predict Pregnancy Outcomes in Women With Chronic Liver Disease.Am J Gastroenterol,2019,114(2):267-275.
[14] Tran TT, Ahn J, Reau NS. ACG Clinical Guideline: Liver Disease and Pregnancy. Am J Gastroenterol,2016,111(2):176-194; quiz 196.
[15] Rahim MN,Theocharidou E,Yen Lau KG, et al. Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.J Hepatol,2021,74(6):1407-1415.
[16] Ponticelli C, Moroni G. Fetal Toxicity of Immunosuppressive Drugs in Pregnancy. J Clin Med,2018,7(12):552.
[17] Bandoli G, Palmsten K, Forbess Smith CJ, et al. A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes.Rheum Dis Clin North Am,2017,43(3):489-502.
[18] Wiest I, Roig A, Antoni C, et al.Safety and efficacy of budesonide during pregnancy in women with autoimmune hepatitis. J Gastrointestin Liver Dis,2022,31(2):256-257.
[19] Heneghan MA,Norris SM,O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut,2001,48(1):97-102.
[20] Saavedra M, Sánchez A, Morales S, et al. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol,2015,34(7):1211-1216.
[21] Alami Z, Agier MS, Ahid S, et al. Pregnancy outcome following in utero exposure to azathioprine: A French comparative observational study. Therapie,2018,73(3):199-207.
[22] Candels LS, Rahim MN, Shah S, et al. Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates. J Hepatol,2021,75(2):324-332.
[23] Chung YY, Heneghan MA. Autoimmune hepatitis in pregnancy: Pearls and pitfalls. Hepatology,2022,76(2):502-517.
[24] Hoeltzenbein M,Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A,2012,158a(3):588-596.
[25] Reggia R, Bazzani C, Andreoli L, et al. The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases. Am J Reprod Immunol,2016,75(6):654-660.
[26] Zheng S, Easterling TR, Umans JG, et al.Pharmacokinetics of tacrolimus during pregnancy.Ther Drug Monit,2012,34(6):660-670.
[27] Kociszewska-Najman B, Mazanowska N, Pietrzak B, et al. Low Transfer of Tacrolimus and Its Metabolites into Colostrum of Graft Recipient Mothers. Nutrients,2018,10(3):267.
[28] Gerosa M, Argolini LM, Artusi C, et al. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol,2018,11(10):987-998.
[29] Wang CW, GrabJ, Tana MM, et al. Outcomes of pregnancy in autoimmune hepatitis: A population-based study. Hepatology,2022,75(1):5-12.
[30] Sajja S, Idler J, Saad J, et al. Acute liver failure in pregnancy due to autoimmune hepatitis. BMJ Case Rep,2021,14(8): e241355.
[31] Terrabuio DR, Abrantes-Lemos CP, Carrilho FJ, et al. Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes. J Clin Gastroenterol,2009,43(4):350-356.
[32] Ludvigsson JF, Marschall HU, Hagstr? m H, et al. Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study. Hepatology,2018,68(2):625-633.
[33] Cauldwell M, Mackie FL, Steer PJ, et al. Pregnancy outcomes in women with primary biliary cholangitis and primary sclerosing cholangitis: a retrospective cohort study. Bjog,2020,127(7):876-884. |
